logo
  

Sturm Ruger Q4 Results Top Estimates

Firearms maker Sturm, Ruger & Company, Inc. (RGR) reported a net loss for the fourth quarter of $14.8 million or $0.77 per share, compared to net income of $26.6 million or 1.33 per share for the year-ago quarter.

In the fourth quarter of 2014, the company recorded an expense of $41.0 million related to the termination and settlement of its defined benefit pension plans.

Excluding items, adjusted net income for the latest quarter was $10.5 million or $0.53 per share.

Net sales for the fourth quarter fell to $122.61 million from $181.90 million a year earlier.

Analysts polled by Thomson Reuters expected the company to earn $0.40 per share on revenue of $101.89 million for the fourth quarter. Analysts' estimates typically exclude special items.

The company also declared a dividend of $0.17 per share for the fourth quarter, payable on March 27 to shareholders of record as of March 13.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT